Publications

Success examples

SMARCA4 biology in alveolar rhabdomyosarcoma

Bharathy N., Cleary M. M., Kim J-A., Nagamori K., Crawford K. A., Wang E., Saha D., Settelmeyer T. P., Purohit R., Skopelitis D., Chang K., Doran J. A., Kirschbaum C. W., Bharathy S., Crews D. W., Randolph M. E., Karnezis A. N., Hudson-Price L., Dhawan J., Michalek J. E., Ciulli A., Vakoc C. R., Keller C.

Oncogene 2022, 41(11):1647-1656.

SMARCA2/4 PROTAC

DOI

PubMed

Success examples

Pharmacological Dissection of the Crosstalk between NaV and CaV Channels in GH3b6 Cells

Réthoré L., Park J., Montnach J., Nicolas S., Khoury J., Le Seac'h E., Mabrouk K., De Pomyers H., Tricoire-Leignel H., Mattei C., Henrion D., Fajloun Z., De Waard M., Legendre C., Legros C.

Int J Mol Sci. 2022, 23 (2):827.

Nav1.2 channel blocker

DOI

PubMed

Success examples

The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type

Tarantelli C., Cannas E., Ekeh H., Moscatello C., Gaudio E., Cascione L., Napoli S., Rech C., Testa A., Maniaci C., Rinaldi A., Zucca E., Stathis A., Ciulli A., Bertoni F.

Explor Target Antitumor Ther. 2021, 2:586-601.

BET PROTAC

DOI

Success examples

Characterizing PROTAC ternary complex formation using Biacore™ SPR systems

Zollman D., Shepherd C., Cytiva, Ciulli A.

Cytiva.

BET PROTAC

DOI

Success examples

Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights

Müller M. R., Burmeister A., Skowron M. A., Stephan A., Bremmer F., Wakileh G. A., Petzsch P., Köhrer K., Albers P., Nettersheim D.